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Cancer is the second leading cause of death in the United States and a leading cause of 
morbidity and mortality worldwide. A promising area of cancer research is focused on 
chemoprevention by nutritional compounds.  Epidemiological studies have shown a 
strong negative correlation between fruit, vegetable and spice intake and rates of cancer. 
Although individual active compounds have demonstrated significant anti-cancer 
activity, an emerging area of research is focusing on the combination of multiple dietary 
compounds on cancer that act synergistically to exert greater effects. In the current study, 
we evaluated potential synergistic effects of capsaicin, an active compound from red chili 
peppers, in combination with 3,3'-Diindolylmethane (DIM), from cruciferous vegetables. 
A synergistic induction of apoptosis and inhibition of cell proliferation was observed in 
multiple cancer cell lines treated with combination of capsaicin and DIM. We also 
observed that these two compounds activated transcriptional activity of p53 and NF-κB 
synergistically. Combination treatment stabilized nuclear p53 and up- or down-regulated 
expression of several target genes that are downstream of NF-κB and p53.  The present 
study suggests capsaicin and DIM work synergistically to inhibit cell proliferation and 
induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-
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Chapter 1: Chemoprevention of Cancer by phytonutrients 
1.1 Introduction 
Cancer is a major public health problem worldwide. In the United States, cancer remains 
the second leading cause of death [1]. The National Cancer Institute (NCI) estimates that 
1,660,290 men and women will be diagnosed with and 580,350 men and women will die 
of cancer of all sites in 2013 [2]. In addition, current cancer treatments remain expensive, 
invasive and ineffective, particularly in the advanced stages. Consequently there has been 
much research focused on the prevention of cancer across the population. The 
epidemiologic review of almost 200 studies that examined the relationship between fruit 
and vegetable intake and cancer incidence clearly demonstrated that individuals with the 
highest intakes of fruits and vegetables have the lowest occurrence of cancers of the lung, 
colon, breast, cervix, esophagus, oral cavity, stomach, bladder pancreas and ovary. The 
risk of cancer for most sites was twice as high in persons whose intake of fruit and 
vegetables was low compared with those with high intake [3].  This strong association 
has been attributed to these foods being rich sources of numerous bioactive compounds 
and has led researchers to focus attention on the active ingredients found in fruits and 
vegetables and the molecular mechanisms of action as potential novel targets for cancer 
prevention and therapy [4-8].   
The active ingredients found in plants have been shown to act on multiple molecular 
targets to suppress carcinogenesis and cancer progression [9-11]. While individual active 
compounds have demonstrated significant anti-cancer activity, an emerging area of 
research is focusing on the combination of multiple dietary compounds on cancer that 
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work synergistically through multiple cell-signaling pathways to exert greater effects [12-
15].  
When discussing therapeutic targets of cancer it is essential to discuss the hallmarks of 
cancer, first identified in a seminal paper by Hanahan and Weinberg in 2000 [16]. They 
identified six biological capabilities acquired during tumorigenesis that offer insight to 
the complexities of cancer as well as targets of therapeutic action of anti-cancer 
compounds. The acquired hallmarks of cancer are sustaining proliferative signaling, 
evading growth suppressors, activating invasion and metastasis, enabling replicative 
immortality, inducing angiogenesis and resisting cell death. Identifying and focusing on 
these particular properties enables concentration on treatments that offer broader efficacy 
specific to tumor cells. 
1.2 Dietary Phytochemicals have chemopreventive properties 
The term “chemoprevention” was first used by Dr. Michael B. Sporn in 1976 to describe 
the use of naturally occurring or synthetic chemical agents to inhibit, delay or reverse the 
disease process of carcinogenesis [17].  Thirty years following that landmark paper there 
have been many naturally-occurring dietary compounds that have been found to possess 
chemopreventive properties [7, 18, 19]. Chemopreventive strategies using 
phytochemicals found in fruits, vegetables, teas and spices are a promising area of cancer 
research because they are inexpensive, safe and readily available while possessing 
diverse inhibitory effects against cancer initiation, promotion, progression and metastasis. 
Much research has been done to elucidate the underlying mechanisms of action of these 
phytochemicals and numerous cellular mechanisms have been implicated in the cancer 
preventative effects of dietary phytochemicals that include antioxidant enzymes, 
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inhibiting cell cycle progression and cell proliferation, inducing apoptosis, suppressing 
oncogenes and activating tumor-suppressor genes by modulating cellular signaling 
pathways [8, 10, 20].  
1.3 Capsaicin induces cell cycle arrest and apoptosis in cancer cells 
Capsaicin is a homovanillic acid derivative (trans-8-methyl-N-vanillyl-6-nonenamide) 
and the spicy component of hot chili peppers that has been studied for its anti-cancer [21-
23], anti-oxidant [24], anti-inflammatory, anti-obesity [25] and analgesic properties[26, 
27]. Capsaicin has been studied in a variety of cancers but the effects on carcinogenesis 
are still controversial due to conflicting results in epidemiological and basic research 
studies [28, 29]. There is also still incomplete data regarding the exact cellular 
mechanisms of how capsaicin induces cell cycle arrest and apoptosis.  
A thorough review of capsaicin by Bley et. al noted that capsaicin appears to inhibit the 
growth of or induce apoptosis in over forty distinct cancer cell lines [30]. The loss of a 
fully functional apoptotic program is considered one of the hallmarks of most, if not all 
types of malignant cells [31]. Apoptosis is an essential barrier to cancer development that 
cancer cells can avoid through multiple strategies, by suppressing pro-apoptotic 
regulators and increasing the function of anti-apoptotic ones. One reason the growth rate 
of cancer cells is much more rapid than that of normal cells is because of deregulation or 
malfunctioning of their cell-growth and cell-death systems. Therefore, induction of 
apoptosis or cell-cycle arrest by dietary compounds such as capsaicin is a promising 
approach to inhibit the promotion and progression of carcinogenesis. In recent years 
cancer research has focused on targeting specific signaling pathways that drive 
inappropriate cell growth and survival.  
4 
 
Capsaicin induces apoptosis in various cancer models including colon [32], prostate [33, 
34], liver [35], esophagus [36], skin [37], leukemia [38], bladder [39], lung [40], pancreas 
[41] and endothelial cells [21], leaving normal cells unharmed [38, 41, 42].  Various 
mechanisms of capsaicin-induced apoptosis have been proposed from different cancer 
cell models.  For example, capsaicin-induced apoptosis is in a p53-dependent mechanism 
in leukemia [38], but in prostate cancer cells, capsaicin’s effect is p53 independent [34]. 
Capsaicin down-regulates the prostate-specific antigen and androgen receptor by 
inhibition of TNFα-stimulated degradation of NF-κB in prostate cancer [34] and inhibits 
VEGF-induced proliferation, DNA synthesis, chemotactic motility, and capillary-like 
tube formation of primary cultured human endothelial cells [21]. Capsaicin-induced 
apoptosis is elevated by co-treatment of the AMPK activator in HT-29 colon cancer cells 
[32], and TRPV6 mediates capsaicin-induced apoptosis in gastric cells through a p53 and 
JNK-dependent pathway [43]. Lu et. al. reported that capsaicin increased ROS and Ca 
2+ 
 
and decreased mitochondrial membrane potential which led to decreased anti-apoptotic 
protein Bcl-2, increased pro-apoptotic Bax and activated caspase-8, -9 and -3 [22]. 
Capsaicin has been shown to possess potent anti-cancer and chemopreventive 
mechanisms through diverse molecular mechanisms but there is still much to be 
discovered regarding the exact methods of actions due to different variations according to 
cancer type and the effect is dependent on the cell or tissue context. 
1.4 3,3’-Diindolylmethane exerts anti-cancer activities through diverse mechanisms  
3,3'-diindolylmethane (DIM) is a major acid condensation
 
product of Indole-3-carbinol 
(I3C) and generated in the acidic environment of the stomach following dimerization of 
I3C, which is an autolysis product of glucosinolate, a naturally occurring component of 
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Brassica species of cruciferous vegetables (cabbage, broccoli, cauliflower, and brussels 
sprouts) [44]. Both I3C and DIM have been established as chemopreventive agents, 
however recent evidence suggests that DIM has greater bioavailability in vivo and more 
effective results in vitro at exerting anti-cancer activity due to its stability [45]. In fact 
DIM, not I3C was detected in serum of women following ingestion of a single dose of 
oral I3C [46]. DIM was also detected in the livers and
 
feces of rodents fed I3C, whereas 
the parent I3C compound could
 
not be detected in tissues of these rodents [47, 48]. Thus, 
the biological effects of I3C may be attributable to DIM, but not I3C in vivo.  
DIM and its derivatives have demonstrated the ability to suppress cell proliferation and 
induce apoptosis in colon cancer cells [49, 50] as well as other types of cancer cells 
including prostate [51], breast [52], bladder [53], pancreas [54], hepatoma [55], and 
umbilical vascular endothelium [56]. Lerner et. al. found that DIM induced apoptosis in 
two colon cancer cell lines, HCT 116 and Colo-320 [57]. DIM induced apoptosis in a 
dose dependent manner in both cell lines as evidenced by DNA fragmentation and 
apoptotic morphology, condensation and fragmentation of the nucleus. They also 
discovered that DIM increased expression of N-myc downstream regulated gene-1 in the 
poorly differentiated Colo-320 cells. Kim et al. found that treatment of two colon cancer 
cell lines, HCT116 and HT-29 with DIM resulted in a substantial decrease in the number 
of viable cells and induced apoptosis in a dose-dependent manner [58]. DIM increased 
the activation of caspase-3, -7, -8, and -9 and enhanced poly (ADP-ribose) polymerase 
cleavage and increased the translocation of cytochrome c and Smac/Diablo from the 
mitochondria to the cytoplasm.   
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Treatment of cancer cells with DIM has been shown to inhibit carcinogenesis, decrease 
cell proliferation, increase apoptosis and induce G1 cell cycle arrest by targeting genes, 
transcription factors and cell signaling cascades that regulate the cell cycle. DIM induces 
apoptosis by inactivating the Akt pathway in breast cancer cells [52] and activating 
TRAIL expression and Nur77 in colon cancer cells [59]. DIM induces anti-tumorigenic 
genes, IFNγ [60] and caveolin expression via a PPARγ-dependent pathway [50, 53] and 
cell cycle arrest by Sp1-mediated activation of p21
WAF1/CIP1
 expression [61]. DIM also 
suppressed metastasis by inhibiting Ras signaling and VEGF-induced neovascularization 
in endothelial cells [56]. DIM suppresses cell proliferation and induces tumor-
suppressing gene NAG-1 expression at the transcription level in HCT-116 cells [62].  
DIM has been studied for years in many cancer lines, most notably in prostate and breast 
cancer but remains very relevant for continuing studies in other cancer cell lines. 
According to the NCI Clinicaltrials.gov homepage there is currently one Phase 2 trial to 
investigate how well DIM works in treating patients with stage I or stage II prostate 
cancer undergoing radical prostatectomy with the rationale that the compound helps to 
slow the growth of tumors.  Further research of DIM in a variety of cancers is needed to 
continue to elucidate the anti-cancer potential of this compound.   
1.5 Physiological concentrations and bioavailability of Capsaicin and DIM 
While there are many published articles regarding in vitro effects of capsaicin and DIM, 
the data on in vivo physiological activity is very limited, particularly in humans, which 
makes it difficult to assess the physiological concentrations and bioavailability of the 
compounds in regards to their physiological potential in humans.   
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In a study of capsaicin distribution in rats following an oral gavage of 30mg/kg body 
weight dose, the researchers observed that nearly 94% of the dose was absorbed and 
maximum concentration of 1.9 μg/ml was observed in the blood 1 hour after 
administration. This concentration decreased to less than half (0.83 μg/ml) in 6 hours and 
was not detectable after 48 hours [63]. During a study on capsaicin and insulin control, 
blood concentrations of the compound was estimated at 2.47 ng/ml (equivalent to 8.1 
nM) in adult males following intake of 0.4 mg/kg body weight [64]  
There have been a few studies in which oral administration of I3C or DIM resulted in 
measureable amounts in serum and tissues, indicating that absorption does occur [47, 65-
67]. During a phase I trial in women, participants were administered 400, 600, 800, 1000 
or 1200 mg of Indole-3-carbinol and then provided serum samples to analyze blood 
concentrations of the metabolites. It was the major product of acid-catalyzed 
condensation, DIM, and not indole-3-carbinol that was detected in serum. While there 
was significant inter-individual variation in the serum concentration, the average max 
concentration at 2 hours post ingestion was 61 ng/mL in the 400 mg dose group and 607 
ng/mL following the 1,000 mg dose. No further increase was observed following a 1,200 
mg dose [46].   
In a study in rats, DIM was present in circulation after 15 minutes following 
administration of 200 mg/kg dose. The maximum plasma DIM concentration achieved at 
1 hour after administration was 0.15 μg/mL [68].  
I3C and DIM are currently sold as nutritional supplements available to consumers in 
health food stores. The recommended maximal human dose of DIM supplement is 2 
mg/kg per day or about 100-200 mg for women and 200-400mg for men.  
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1.6 Toxicity of Capsaicin and DIM  
Published studies on the toxicity of capsaicin have been inconsistent with both positive 
and negative effects being reported in some of the typical genetic toxicology assays.[69-
73] Inconsistencies between the tests may be due to methodology as well as the source of 
capsaicin, whether it is pure synthetic capsaicin or extracted from chili peppers. 
Toxicology studies that analyzed pure capsaicin may differ in results attained with 
extracts because of inconstant contents and potentially toxic impurities such as aflatoxins 
B1 and G1 in the extracts [30].   
Chili extracts were found to be mutagenic in five strains of Salmonella typhimurium as 
well as in the mammalian micronucleus test [74]. However, an Ames test with highly 
pure synthetic capsaicin and found no mutagenic activity in five different bacteria strains. 
The same group looked at in vitro chromosomal aberrations assays using human 
peripheral blood lymphocytes and found no significant increases in chromosomal 
aberrations, polyploidy, or endoreduplication [70].  
Another paper using high-purity capsaicin also found no genotoxic activity in the 
bacterial mutation and chromosome aberration tests. Also, no evidence of cytotoxicity or 
genotoxicity was observed in rat bone marrow micronucleus test. The researcher’s 
conclusion at the end of the paper was “that pure capsaicin is not active in the standard 
battery of genotoxicity assays recommended by the International Conference on 
Harmonisation for evaluation of new medicines. Earlier reported in vitro genotoxic 




There have also been inconsistent reports on the effects of high chili consumption and 
stomach cancer in epidemiological studies. In Mexico and India, human dietary exposure 
to capsaicin from high intakes of chili peppers has been linked with gastric cancer [76, 
77] but a study done in Italy showed a protective effect [78]. 
Indole-3-carbinol and DIM have also had inconsistent toxicology reports. A study found 
that DIM induced immunotoxic effects including decreases in various immune cells and 
increase in apoptosis in the spleen of neonatal mice [79]. However a long-term toxicity 
study analyzed both Indole-3-Carbinol (I3C) and DIM intake in Sprague-Dawley (SD) 
rats and found no toxic effects. The rats were fed a control diet, 1 or 10x the current 
human dose found in nutritional supplements of 2 mg/kg of absorption-enhanced DIM or 
5-7x the maximal recommended dose of I3C. No significant differences were observed 
between the groups and there was no observed toxicity from either I3C or DIM, even 
after 12 months of treatments[67].  
1.7 NF-κB targeting in cancer  
The transcription factor NF-κB is a regulator of genes encoding cytokines, cytokine 
receptors, and cell adhesions molecules that control immune and inflammatory response. 
NF-κB plays a major role in development and progression of cancer because it regulates 
more than 500 genes and aberrant NF-κB regulation has been observed in many cancers 
[80]. NF-κB can affect all six hallmarks of cancers through the transcriptional activation 
of genes associated with cell proliferation, angiogenesis, metastasis, tumor promotion, 
inflammation and apoptosis. The NF-κB family is composed of five members: Rel A 
(p65), RelB, REL (cRel), NF-κB1 (p50 and its precursor p105) and NF-κB2 (p52 and its 
precursor p100).  
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Under normal conditions, NF-κB is sequestered in the cytoplasm, bound to a member of 
the IkB family of inhibitory proteins. Stimulation by one of a range of signals results in 
phosphorylation and ubiquitination of IkB followed by proteosome-mediated 
degradation. Dissociation from IkB results in NF-κB nuclear translocation and 
transcriptional regulation of numerous target gene that have both pro and anti-apoptotic 
effects [52, 81-83].  
The roles of NF-κB in cancer progression and anti-cancer therapeutics are complex. In 
fact, different activation pathways of NF-κB may cause the expression of proteins that 
promote apoptosis like Fas-L, c-myc, p53, IκBα, or inhibit apoptosis through Traf2, IAP 
proteins, Bcl-2 like proteins [84]. Also, NF-κB activation has been shown to control the 
regulation of cell cycle proteins such as cyclin D1 and CDK2 kinase under certain 
stimulus.  
Typically, NF-κB activation is associated with the action of inflammatory cytokines such 
as TNF and bacterial or viral infection. The activity of the NF-κB family of transcription 
factors, and RelA (p65) in particular, is closely linked to p53 and Mdm2 function [85, 
86]. NF-κB is also activated by many stimuli that induce p53 activity, such as DNA-
damaging agents and other forms of cellular stress. In addition to targeting genes, NF-kB 
can interact indirectly with p53 to regulate many genes related to tumorigenesis through 
transcriptional cross-talk [87]. The NF-κB subunit RelA (p65) has been shown to inhibit 
p53 dependent transactivation, while p53 can also suppress NF-κB transcriptional 
activity. One example of indirect p53-dependent repression is the regulation of the Cyclin 




1.8 p53 targeting in cancer 
p53 is a well-known tumor-suppressor that is mutated in about half of all cancers 
[89].  Therefore, reactivating its function to suppress cancer progression has been the 
focus of much research. Of the roughly 150 genes targeted by p53, most are associated 
with regulation of genomic integrity, the cell cycle, DNA repair mechanisms and cell 
death in response to a variety of stress signals or damage to the cell. These processes 
function to prevent inappropriate proliferation of damaged cells. When a cell is 
confronted by stress, p53 is stabilized in the nucleus, where it initiates cellular responses 
through transcriptional activation or repression of target genes resulting in cell cycle 
inhibition, apoptosis, genetic stability and inhabitation of angiogenesis [90, 91]. 
Phosphorylation at the Ser-15 residue of p53 is critical for p53-dependent transactivation. 
Accumulation of p53 by inhibiting the interaction between p53 and MDM2 also 
stimulates p53-dependent transactivation.  While much of the activity of p53 is in the 
nucleus, it can also act outside of the nucleus to induce apoptosis by binding with anti-
apoptotic proteins such as Bcl-2[92]. 
Capsaicin has demonstrated its ability to induce phosphorylation of p53 at the Ser-15 
residue in myeloid leukemia cells (NB4) which also resulted in apoptosis [93]. 
Interestingly, they found the results were not as significant in p53 defective cells. In 
contrast, Mori, et al. found that capsaicin inhibited the growth and induced apoptosis in a 
p53-independent manner in prostate cancer cells in vitro and xenografts in vivo [94]. 
Treatment with Capsaicin in urothelial cancer cells resulted in increased expression of 
p53, and phosphorylation at Ser 15, 20 and 392 as well as significant cell cycle arrest and 
apoptosis [95]. Taken together, these results suggest that p53 and NF-κB are targets of 
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capsaicin’s anticancer activity, but that it holds antiproliferative activity independent of 
p53 as well.   
1.9 Synergistic effect of multiple phytochemicals 
Studying the synergism of multiple phytochemicals holds promise for enhanced anti-
cancer capabilities because the ability of chemopreventive phytochemicals to prevent 
tumor development is likely the outcome of the combination of several distinct sets of 
intracellular effects, rather than any one single biological response. Cancer is often the 
result of the accumulation of multiple mutations in genes that result in disruption of 
normal cell signaling and maintenance so it is probable that targeting multiple actions 
would result in greater results [14]. Many studies have suggested that phytochemicals in 
fruits, vegetables and spices can have complementary and overlapping mechanisms of 
action, including modulation of detoxification enzymes, scavenging of oxidative agents, 
stimulation of the immune system, regulation of gene expression in cell proliferation and 
apoptosis, hormone metabolism, and antibacterial and antiviral effects [5, 15, 96, 97]. 
Combination treatment may also result in therapeutic synergy between individual 
compounds at physiologically relevant doses, allowing for a reduction in their individual 
concentrations and toxicities [98].  The therapeutic doses for individual anti-carcinogens 
may far exceed what an individual could naturally ingest from plant sources however the 
combination of several antitumorigens at subtherapeutic levels have been shown to result 
in significant antitumor effects [15, 99, 100]. Thousands of phytochemicals are present in 
fruits and vegetables and differ in molecular size, polarity, and solubility, which may 
affect the bioavailability and distribution of each phytochemical. Therefore, use of these 
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dietary compounds with distinct molecular mechanisms is beginning to receive attention 
and is considered more promising for higher efficacy in cancer research.  
It is currently common practice in clinical settings to use combination drug therapies in 
the treatment of cancers to overcome the common problem of drug resistance and 
improve outcomes [101, 102]. A promising area of research is identifying dietary 
compounds that can exert chemotherapeutic actions alone or to sensitize cancer cells to 
traditional chemotherapy drugs [7, 20, 103]. A major concern regarding the prevention 
and treatment of cancer is the relative toxicity of chemopreventive and/or therapeutic 
agents, and many of these agents are associated with undesirable dose-related toxicity. 
Dietary compounds are therefore especially appealing for prevention and treatment of 
cancer due to their low toxicity.  
Modern cancer research is seeking out ways to improve the efficacy of chemotherapy 
through the development and/or identification of novel chemotherapeutic agents and 
through identification of novel molecular targets. Combining dietary compounds to exert 
greater anti-cancer properties and identifying their molecular targets will have obvious 
benefits in regards to treatment options available for patients.  
The high number of publications suggests that novel combination treatment with 
common cancer therapies and chemopreventive agents may enhance anti-tumor activity 
through synergic action [14, 104, 105]. Combining cherry extract with suboptimal levels 
of sulindac reduced total tumors in the small intestine of Apc
Min+
  mice compared to mice 
fed sulindac alone [106]. In humans, a combination of supplements curcumin and 
quercetin regressed adenomas in patients with FAP [107]. DIM synergistically 
suppressed the proliferation of human colorectal cancer cells when combined with 
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sulforaphane [108]. DIM in combination with genistein resulted in decreased 
proliferation by working on Estrogen and Androgen receptors in vitro LNCaP PCa cells 
[109]. Most notably, they found that the combination of the two enabled them to use low 
concentrations of the compounds while still seeing significant results. Hwang et al. found 
that genistein with capsaicin resulted in decreased breast cell cancer proliferation and 
increased apoptosis in vitro and in vivo in a breast cancer rat model. [13] They 
discovered that in TPA-treated conditions both in vivo and in vitro downregulated MAP 
kinase and COX 2 and activated AMPK to exert anti-cancer activity.  Manikandan et al. 
studied the synergistic anticancer activity of curcumin and catechin in vitro in human 
colon cancer cells. They found that individually the compounds inhibited growth but in 
combination had the highest level of growth inhibition [12]. They found the dietary 
compounds together induced cytotoxicity, nuclear fragmentation and condensation and 
DNA fragmentation associated with apoptosis but did not analyze the molecular actions 
that resulted in the apoptosis. Furthermore, in previous data, mixture of I3C and 
resveratrol was much more effective in NAG-1 induction compared to resveratrol alone 
[62]. Therefore, use of multiple dietary compounds with distinct and complementary 
molecular mechanisms and gene targets is beginning to receive much attention and is 
considered promising for cancer research.  
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CHAPTER 2: Materials and Methods 
2.1. Cell culture and reagents 
Human colorectal adenocarcinoma cells HCT116, LoVo, CaCo2, SW480, HT-29, human 
lung cancer A549 and human prostate cancer PC3 cells were purchased from American 
Type Culture Collection (ATCC; Manassas, VA) and grown in Dulbecco’s modified 
Eagle medium (DMEM/F12) supplemented with 10% fetal bovine serum (FBS). Normal 
human colon cells, CCD112CoN was purchased from ATCC and grown in Eagle’s 
Minimal Essential Medium (EMEM) supplemented with 10% FBS.  The cells were 
maintained at 37 ºC under a humidified atmosphere of 5% CO2.   
2.2 Cell proliferation and Apoptosis 
Human colorectal adenocarcinoma cells HCT116, LoVo, SW480, CaCo-2, HT-29, 
human lung cancer cells A549, human prostate cancer cells PC3 and normal human colon 
cells, CCD112CoN were treated with different concentrations of capsaicin (0-100 µM), 
DIM (0-25 µM) or combination (50 µM capsaicin and 12 µM DIM). Capsaicin was 
dissolved in ethanol and DIM was dissolved in dimethyl sulfoxide (DMSO). Ethanol and 
DMSO was used as a vehicle in the control groups and the final concentrations of ethanol 
and DMSO did not exceed 0.1% (v/v).  
Cell proliferation was assessed by the MTT [(4,5-dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium bromide] (Sigma, St. Louis, MO) method.  Cells were plated at 4000 
cells/well onto a 96-well plate in three replicates and grown overnight. The cells were 
treated with different concentrations of capsaicin (0-100 µM), DIM (0-25 µM) or 
combination (50 µM capsaicin and 12 µM DIM) in media supplemented with 1% Fetal 
Bovine Serum (FBS) for 24 and 48 hours at 37ºC under 5% CO2. Then, cells were 
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incubated with 20 μL of MTT solution for 3 hours at 37ºC.  The optic density was 
recorded at 490 nm using an enzyme-linked immunosorbent assay plate reader (Bio-Tek 
Instruments Inc., Winooski, VT).  
Apoptosis for HCT-116 was performed using FACS analysis. Briefly, both attached and 
floating cells were collected and resuspended in 80% ice-cold ethanol. After overnight at 
−20 °C, the cells were rehydrated with PBS and stained with 70 µM propidium iodide 
solution including 1 mg/mL RNase A. Apoptosis and cell cycle distribution were 
analyzed using Beckman Coulter Epixs XL flow cytometer equipped with EXPO32 ADC 
and ModiFit LT software. And apoptosis for other human colorectal cancer cells (LoVo, 
CaCo2, HT-29 and SW480) was tested with Cell Death Detection ELISA
PLUS
 Kit (Roche 
Diagnostics, Indianapolis, IN) according to the manufacturer’s instruction.  
2.3 Transient transfection and luciferase assay 
Transient transfection for NF-κB Luc and p53 Luc plasmid was performed using a Polyjet 
DNA transfection reagent (SignaGen Laboratories, Ijamsville, MD) according to the 
manufacturer’s instructions. HCT116 cells (2x10
5 
cells/well) are plated in 12-well plates 
in three replicates and incubated overnight. The next day, plasmid mixtures containing 1 
μg of NF-κB Luc or p53 Luc and 0.1 μg of pRL-null were transfected into the cells for 24 
hours. The cells were washed and harvested in 1x luciferase lysis buffer. The luciferase 
activity was measured and normalized to the pRL-null luciferase activity using a dual-
luciferase assay kit (Promega, Madison, WI). 
2.4 Isolation of cytosol and nucleus fraction 
Cytosol and nuclear fraction of cells were prepared according to the manufacturer’s 
protocols of a nuclear extraction kit (Active Motif, Carlsbad, CA). Briefly, after HCT116 
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cells were treated in the compounds for 24 hours, the cells were washed twice with ice-
cold PBS containing phosphatase inhibitors (Sigma Aldrich, St. Louis, MO). Cells were 
harvested with hypotonic buffer containing detergent and incubated at 4ºC for 15 min. 
The supernatants (cytoplasmic fraction) were collected after centrifugation at 14,000 g 
for 1 minute at 4ºC, and stored at -80ºC. For nuclear fractions, cell pellets were 
resuspended with lysis buffer and incubated at 4ºC for 30 minutes under shaking. After 
30 min, nuclear suspensions was centrifuged at 14,000 g for 10 minutes at 4ºC, and the 
supernatants (nuclear fraction) were stored at -80ºC for further analysis 
2.5 SDS-PAGE and Western Blot 
The cells were washed with ice-cold 1x phosphate-buffered saline (PBS), and lysed in 
radioimmunoprecipitation assay (RIPA) buffer (Boston Bioproduct Inc, Ashland, MA) 
supplemented with protease and phosphatase inhibitor cocktail (Sigma Aldrich) and 
centrifuged at 12,000 g for 10 minutes at 4º. After protein concentration is determined by 
the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL), equal amounts of 
proteins were subjected to 10% or 12% SDS-PAGE, and the separated protein was 
transferred onto nitrocellulose membranes (Osmonics, Minnetonka, MN). The 
membranes were blocked for non-specific binding with 5% non-fat milk in Tris-buffered 
saline containing 0.05% Tween 20 (TBS-T) for 1 hour at room temperature and then 
probed with primary antibodies overnight at 4ºC, followed by incubation with horse 
radish peroxidase (HRP)-conjugated immunoglobulin G (IgG) for 1 hour at room 
temperature. Chemiluminescence was detected with Pierce ECL Western Blotting 
substrate (Thermo Scientific) and visualized by Chemidoc MP Imaging system (Bio-Rad, 




Total RNA was isolated from cells using the RNeasy Micro Kit (QIAGEN, Valencia, 
CA) and cDNA synthesized using cDNA synthesis kit. Quantitative real-time PCR was 
performed and targeted primers for Bak, p21 and GAPDH were used. Amplification was 
performed under conditions of 95 °C for 10 min, followed by 35 cycles of 94 °C for 30 s, 
55 °C for 30 s, and 72 °C for 45 s. Primers sequences are following: Bak: forward    
5’-TCTGGCCCTACACGTCTACC-3’, and reverse 
5’ACAAACTGGCCCAACAGAAC-3’, p21: forward 
5’GAGCGATGGAACTTCGACTT-3’, and reverse  
5’-CAGGTCCACATGGTCTTCCT-3’, GAPDH: forward 
5’ACCCAGAAGACTGTGGATGG-3’, and reverse 
5’TTCTAGACGGCAGGTCAGGT-3’. Reaction products were analyzed on 1% agarose 
gel.  
2.7 Statistics 
Statistical analysis was performed with IBM SPSS and the data was analyzed by 1-way 
ANOVA with Tukey’s post hoc comparisons. Data is expressed as means ± SD and 
differences were considered significant at P < 0.05.
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Chapter 3: Synergistic anti-cancer properties of capsaicin and DIM 
The initiation, promotion and progression of cancer are typically a long-term process that 
proceeds through many steps. There is increasing evidence from cancer epidemiological 
and pathological studies suggesting that many human cancers could be prevented or their 
progression slowed down or even halted with chemoprevention [3, 4]. Chemopreventive 
agents can act as blocking agents, which impede the initiation stage, or suppressing 
agents, which arrest or reverse the promotion and progression of cancer by targeting 
factors that control cell proliferation, differentiation, senescence or apoptosis. Many 
active compounds found in fruits, vegetables and spices have been shown to possess the 
ability to both block and suppress carcinogenesis. The anti-carcinogenic function of these 
compounds might be attributed to a combination of these effects and their ability to target 
multiple pathways [20].  
Typically the growth rate of cancer cells is much more rapid than that of normal cells 
because of malfunctioning or dysregulation of their cell-growth and cell-death 
mechanisms. Therefore, induction of apoptosis or cell-cycle arrest by dietary 
chemopreventive compounds presents a promising approach to inhibit the promotion and 
progression of carcinogenesis and to remove genetically damaged, precancerous or 
cancerous cells from the body. We and others reported that several phytochemicals 
including capsaicin, 6-gingerol, epicatechin, indole-3 carbinol and DIM possess potent 
anti-cancer effects. In previous study, we screened the combinational effects of capsaicin 
with other dietary compounds based on expression of tumor suppressor genes such as 
NAG-1 and ATF3. As a result, we found that combination of capsaicin and DIM showed 
synergistically induced expression of these genes and programmed cell death. The 
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hypothesis is that the combination of capsaicin and DIM can have significant synergistic 
anti-cancer effects at relatively lower concentrations than individual compounds. To test 
this hypothesis, multiple cancer cell lines were treated with individual concentrations 
(100 μM Capsaicin and 25 μM DIM) and then combination of the two at half the 
concentration of the individual ones (50 μM Capsaicin and 12 μM DIM). The results 
suggest that the combination of Capsaicin and DIM can have significant synergistic anti-
cancer effects as compared to higher concentrations of the individual compounds and 
these are due to mechanisms involving p53 and NF-κB. 
3.1 Combination treatment of Capsaicin and DIM suppresses cell proliferation in 
multiple cancer cell lines 
To explore the effect on cell proliferation of individual and combination treatment with 
capsaicin and DIM in multiple cell lines, normal human colon CCD-112CoN (Fig 3.1A), 
human colon adenocarcinoma HCT116 (Fig 3.1B), LoVo (Fig 3.1C), CaCo2 (Fig 3.1D), 
HT-29 (Fig 3.1E), SW480 (Fig 3.1F), human lung carcinoma A549 (Fig 3.1G) and 
human prostate carcinoma PC3 (Fig 3.1H) were treated with the stated concentrations of 
the compounds. As shown in Fig 3.1A, treatment of single compounds did not change 
cell proliferation in normal human colon CCD-112Con cells. Co-treatment of capsaicin 
and DIM slightly but significantly decreased cell proliferation on day 1 but not on day 2. 
Overall, this result is in agreement with the literature that suggests that the individual 
compounds of capsaicin and DIM are nontoxic to normal cells [30, 67, 95]. Although the 
pattern that human colorectal cancer cells to respond to capsaicin are different according 
to types of cells, combination of low dose capsaicin and DIM showed similar activity 
with high dose of single compounds in terms of suppressing cell proliferation (Fig 3.1.B-
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F). In addition, synergistic suppression of cell growth was observed in non-colorectal 
cancer cells (Fig. 3.1.G,H). Taken together, these results indicate that the combination of 
the two compounds restricts cell proliferation in multiple cancer cell lines while being 
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Figure 3.1 Combination treatment inhibits cell proliferation in multiple cancer cell 
lines, but not normal human colon cells.  Normal human colon CCD112CoN (A) 
HCT116 (B), LoVo (C), CaCo-2 (D), HT-29 (E), SW480 (F), A549 (G), and PC3 (H) 
cells were plated onto a 96-well plate and grown overnight. The cells were treated with 
different concentrations of capsaicin (0-100 µM), DIM (0-25 µM) or combination (50 
µM capsaicin and 12 µM DIM) in media supplemented with 1% FBS for 24 and 48 hours 
at 37ºC under 5% CO2. Cell proliferation was assessed by the MTT [(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide] (Sigma, St. Lous, MO) method. 
The optic density was recorded at 490 nm using an enzyme-linked immunosorbent assay 
plate reader (Bio-Tek Instruments Inc., Winooski, VT). Values are means ± SD, n = 3. 
































































3.2 Synergistic induction of apoptosis in multiple cancer cells lines.  
Apoptosis is an essential way for the body to eliminate abnormal cells that pose a threat 
to the organism’s life and is an essential barrier against tumorigenesis. We depend on a 
functional apoptotic program for proper tissue development and maintenance to eliminate 
cells that are irreparably damaged. However, if a cell is able to evade apoptosis with 
certain damages or mutations that inhibit apoptosis and that cell continues to multiply, 
this can lead to tumor initiation, progression and/or metastasis [31]. Also, there is strong 
evidence that defective apoptosis is a cause of drug resistance and cancer treatment 
failure. Since it is the alteration of apoptosis that contributes both to tumor development 
and drug resistance, compounds that can trigger apoptosis in previously resistant cells has 
been the focus of much research [110, 111].  
To determine whether capsaicin and DIM had a synergistic effect on apoptosis, the cells 
were treated with various concentrations of capsaicin individually (100 μM) and DIM 
individually (25 μM) as well as in combination (50 μM capsaicin and 12 μM DIM) and 
compared with a control group. While the individual compounds resulted in apoptosis, 
interestingly the combination treatment of capsaicin and DIM induced a marked 
reduction in the number of viable cells in all cell lines, which suggest these compounds 






















































































Chapter 4: Discussion and Concl 
 
 

















Figure 3.2 Synergistic effects of capsaicin and DIM in apoptosis of multiple cell 
lines. Apoptosis of different human colorectal cancer cells, HCT116 (A), LoVo (B), 
CaCo2 (C), HT-29 (D) and SW480 (E), was tested with FACS (HCT-116 cells) and Cell 
Death Detection ELISA
PLUS
 Kit (Roche Diagnostics, Indianapolis, IN) for LoVo, CaCo2, 
HT-29 and SW480 cells according to the manufacturer’s instruction. Values are means ± 
SD, n = 3. Means without a common letter differ, P < 0.05.  
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3.3 Combination treatment increases transcriptional activity of p53 and increases 
expression in the nucleus. 
A major reason that cancer cells are able to evade apoptosis and grow in a rapid and 
uncontrolled manner is through mutations in the p53 tumor suppressor gene [112]. The 
p53 gene is the most frequently mutated gene in human cancers and the cells with p53 
mutation will lack the DNA-damage-sensing capability that would normally induce cell 
cycle arrest, DNA repair and the apoptotic cascade.  This is seen in p53 null (-/-)  and p53 
mutant cells that are resistant to drug induced apoptosis [89]. One reason for this is that 
the majority of the genes and proteins that are transcriptional targets of p53 regulate the 
cell cycle, senescence, DNA repair and apoptosis; all essential barriers to tumor initiation 
and progression. Therefore, targeting p53 and the downstream transcriptional targets in 
cancer cells offer promising therapeutic interventions for cancer prevention and treatment 
[91].   
p53 has been shown to have two mechanisms for regulating cell cycle and initiating 
apoptosis [112]. Certain stimuli such as oxidative stress and genotoxic injury can cause 
p53 nuclear accumulation and activation of downstream proapoptotic gene expression 
such as PUMA, Bak or Bax to induce cell death. However, p53 has also been shown to 
have transcription-independent proapoptotic effects in the cytoplasm through direct 
interactions with the Bcl-2 family proteins [113]. Since it was observed that capsaicin and 
DIM can initiate apoptosis and cell cycle arrest, the transcriptional activity and 
expression of p53 was analyzed. 
HCT116 cells were seeded on 12 well plates in three replicates. After growth overnight, 
the cells were transfected with plasmid containing 1 μg of p53 luciferase plasmid and 0.1 
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μg pf pRL-null vector for 24 hours at 37ºC. The transfected cells were then treated with 
vehicles as the control, capsaicin and DIM individually or in combination for 24 hours. 
The cells were harvested in 1x luciferase lysis buffer, and luciferase activity was 
measured. The transcriptional activity of p53 significantly increased with combination 
treatment as compared with the individual compounds (Fig 3.3A).   
To assess the level of p53 proteins in the cells, HCT116 cells were treated with the 
compounds for 24 hours, harvested and the cytoplasm and nucleus were separated. The 
cell lysates were analyzed by Western Blotting for p53 and TATA-binding protein (TBP) 
was used as nuclear fraction marker and loading control in nuclear fraction. As a result, 
there was increase in the level of p53 in the nucleus of the cells incubated with the 
combination of both capsaicin and DIM (Fig 3.3B). p53 protein levels in the nucleus are 
usually kept low by rapid degradation through ubiquitin-dependent proteolysis [114]. The 
levels of p53 within a cell are not as dependent on the creation of new p53, but on the rate 
of degradation by the MDM2 protein. Activation of p53 depends on the inhibition of this 
degradation and subsequent stabilization of the p53 protein which is allowed to rapidly 
accumulate. It is believed that accumulation of p53 in nucleus after co-treatment of 
capsaicin and DIM is caused by enhanced p53 stability. Mechanisms such as 
phosphorylation at serines 15, 37 or 20 have been shown to reduce the interaction 
between p53 and MDM2 in vitro and result in nuclear stabilization and activation [115]. 
p53 has demonstrated transcription-independent proapoptotic effects as well, as it has 
been shown that particular mutations that prevent the transactivating functions of p53 
and/or the deletion of p53 nuclear localization signal which causes its retention in the 
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cytoplasm, do not completely eliminate p53 apoptosis [113, 116].  The cytoplasmic 






















Figure 3.3 Combination treatment synergistically increases transcriptional activity 
of p53 and increases expression of p53 in nucleus.  HCT116 cells were transfected 
with plasmid containing 1μg of p53 luciferase plasmid and 0.1 μg pf pRL-null vector for 
24 hours at 37ºC.  The transfected cells were then treated with the vehicle as the control, 
100 μM capsaicin, 25 μM DIM individually or combination for 24 hours. The cells were 
harvested in 1x luciferase lysis buffer, and luciferase activity was measured. Values are 
means ± SD, n = 3. Means without a common letter differ, P < 0.05. (A) HCT116 cells 
were treated with 100 μM capsaicin, 25 μM DIM individually or combination for 24 
hours. Cells were washed with ice cold PBS and harvested. The cytoplasm was separated 
from the nucleus and cell lysates were analyzed by Western Blot for p53, TATA-binding 
protein (TBP) and actin. TBP was used as a nuclear loading control. (B)  
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3.4 Effect of combination treatment on expression of target proteins that regulate 
apoptosis and cell cycle. 
After observation of the effect of combination treatment on cell proliferation, apoptosis 
and p53 transcription and expression it was hypothesized that genes and proteins known 
to be regulated by p53 could be modulated through combination treatment. Western blot 
analysis was used to analyze target proteins that are involved in these processes and RT-
PCR was used to confirm mRNA levels of the target genes.  
Cell cycle progression is a sequential process that directs dividing cells through G1, S, 
G2 and M phases. Transitions between G1-S or G2-M phases function as checkpoints to 
halt cell division if necessary. The balance between interactions among cyclins, cyclin-
dependent kinases (CDKs) and CDK inhibitors (CDIs) regulates the progression of the 
cell cycle and disruptions of any of these proteins can effect and block the continuous 
proliferation of tumorigenic cells [118, 119].  
Two well-known regulators of the cell cycle are the tumor suppressor proteins, p21 and 
p27. Increases of these two proteins result in suppression of the actions of CDK4 and 
CDK6, therefore preventing a cell from continuing through the cell cycle and 
proliferating [120]. 
Combination treatment resulted in increased expression of both p21 and 27 with 
subsequent inhibition of CDK4 and CDK 6 (Fig 3.4A).  
There are several pathways which regulate apoptosis within a cell. The extrinsic pathway 
is triggered by the binding of a death receptor, such as Fas or tumor necrosis receptor 1, 
with this extracellular ligand, Fas-L. When this binding occurs, Fas-L combines with Fas 
to form a death complex. The Fas/Fas-L complex recruits death domain-containing 
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protein (FADD) and pro-caspase-8 to become the death-inducing signaling complex 
which results in a cascade of reactions which result in the execution of the apoptotic 
program [110].  
Another very important pathway is the intrinsic pathway which is regulated by the Bcl-2 
family of cytoplasmic proteins. It directly interacts many pro- and anti-apoptotic 
members that determine whether the cell survives or begins down the apoptotic pathway. 
Treatment of HCT-116 cells with the combination of capsaicin and DIM resulted in 
increased expression of multiple pro-apoptotic proteins (Fig 3.4B). Bak, Bax, BID, 
PUMA (p53-upregulated modulator of apoptosis) and Fas-L are all pro-apoptotic proteins 
that are downstream of p53.  
Research into mechanisms that promote cell survival and resistance to apoptosis have 
identified a number of genes that are up-regulated by NF-κB. Expression of several genes 
including Bcl-2, Bcl-Xl, cIAP, survivin, cyclin D1, TRAF1, TRAF2 have been reported 
to be targets of NF-κB that promote tumorigenesis through resistance to apoptosis and 
cell cycle arrest [82]. Combination treatment resulted in downregulation of pro-survival 
protein, Bcl-2 (Fig 3.4C).  Bcl-2 inhibits apoptosis and has been shown to be over-
expressed in many types of cancer cells [121].  Reduced Bcl-2 expression promotes 
apoptotic responses to anticancer drugs, while increased expression leads to resistance to 
chemotherapeutic drugs and radiation therapy and is a target to prevent drug resistance 
and increased apoptosis. Tumor necrosis factor receptor-associated factor 2 and -3 
(TRAF2 and TRAF3) have also been shown to be oncogenes that regulate the 
noncanonical signaling of NF-κB. Previous groups have shown that suppression of 
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TRAF2 and TRAF3 results in decreased proliferation and tumorigenesis [122]. 
Combination treatment resulted in downregulation of these two oncogenes (Fig 3.4C). 
Following treatment with capsaicin and DIM, cells were harvested and reverse 
transcription-polymerase chain reaction was performed to analyze levels of mRNA for 
p21 and Bak (Fig 3.4D). Increased levels of p21 and Bak mRNA were identified 
following treatment of both capsaicin and DIM.  
Nonsteroidal anti-inflammatory drug (NSAID) activated gene-1 (NAG-1) is a divergent 
member of the transforming growth factor-beta (TGF-β) superfamily that has been shown 
to possess various tumor suppression activities both in vitro as well as in mouse models 
[62, 123, 124].  The expression of NAG-1 has been shown to induce apoptosis in 
colorectal cancer cells[62], pancreatic cancer [125] and prostate cancer [126]. Given the 
potential of this gene, researchers have focused on compounds that can increase the 
expression of this gene as a target for anti-cancer drugs and phytochemicals. When 
HCT116 cells were treated with capsaicin and DIM, the combination resulted in a 
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Figure 3.4 Analysis of protein and mRNA expressions in HCT116 cells treated with 
Capsaicin and DIM. HCT116 cells were treated with different concentrations of 
capsaicin (0-100 µM), DIM (0-25 µM) or combination (50 µM capsaicin and 12 µM 
DIM) and incubated for 24 hours. The cells were harvested and cell lysates were 
analyzed with Western Blot for target proteins.  Proteins involved in regulating the cell 
cycle,p21, p27, CDK4 and CDK6 were analyzed (A). Proteins with pro-apoptosis 
functions, Bak, BID, Bax, Puma and Fas-L were analyzed (B). Anti-apoptotic proteins 
Bcl-2, Traf2, Traf3 were analyzed (C). HCT116 cells were treated with capsaicin 
(100μM), DIM (25μM) or combination (50 μM capsaicin and 12 μM DIM) and then total 
mRNA was harvested. RT-PCR was performed (D). HCT116 cells were treated with 
various concentrations of capsaicin and DIM and harvested. Western Blot for    NAG-1 






3.5 Modulation of target genes is p53 dependent 
The p53 tumor suppressor protein performs a critical role in inducing apoptosis. Many of 
the proapoptotic Bcl-2 family members including PUMA, Bax and Bak have been 
reported to be transcriptional targets of p53 [117]. Also the cell cycle regulating proteins, 
p27 and p21 are also transcriptional targets of p53 [91]. To test if the target genes 
modulated by combination treatment identified previously were dependent on p53, 
HCT116 p53 null cells were plated and treated with various concentrations of capsaicin 
individually (100 μM) and DIM individually (25 μM) as well as in combination (50 μM 
capsaicin and 12 μM DIM). The cells were harvested and the lysates were subjected to 
analysis by Western Blot. Interestingly, p27, p21, Fas-L and Bak were all upregulated in 
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Figure 3.5 Modulation of target proteins in a p53-dependent manner. HCT116 Wild 
Type (WT) and HCT116 p53 null (-/-) cells were treated with different concentrations of 
capsaicin (0-100 µM), DIM (0-25 µM) or combination (50 µM capsaicin and 12 µM 
DIM) and incubated for 24 hours. The cells were harvested and cell lysates were 















3.6 Combination treatment increases transcriptional activity of NF-κB 
NF-κB family of transcription factors have been shown to play an important role in 
regulating apoptosis, both in inducing apoptosis or blocking it. It has also been shown to 
act on cell cycle regulation through sensitizing or desensitizing a cell to apoptotic signals. 
The dual roles of NF-κB transcription factors have led to much debate regarding its role 
in cancer initiation and progression [80, 83].  Given that both p53 and NF-κB are 
transcription factors stimulated with cellular stress, and the compounds already have 
demonstrated the ability to increase p53 transcriptional activity, the transcriptional 
activity of NF-κB was measured. 
HCT116 cells were seeded on 12 well plates in three replicates. After growth overnight, 
the cells were transfected with plasmid containing 1 μg of NF-κB luciferase plasmid and 
0.1 μg pf pRL-null vector for 24 hours at 37ºC.  The transfected cells were then treated 
with the vehicle as the control, capsaicin and DIM individually or in combination for 24 
hours. The cells were harvested in 1x luciferase lysis buffer, and luciferase activity was 
measured (Fig 3.6A).  Interestingly, the transcriptional activity of NF-κB significantly 
increased with combination treatment as compared with the individual compounds. 
p53 and NF-κB have been shown to be induced by similar stimuli including DNA-
damaging agents, hypoxia, oxygen free radicals and ionizing radiation and there is 
evidence to suggest p53 itself induces NF-κB activation [127, 128]. NF-κB activity in 
cancer is complex as there is evidence to show that it both inhibits and contributes to 
apoptosis depending on the stimulus, cell line and other factors. The result of this project 
supports others that have shown that NF-κB and p53 play important roles in cell cycle 












Figure 3.6 Synergistic increase in transcriptional activity of NF-κB.  
HCT116 cells were transfected with plasmid containing 1 μg of NF-κB luciferase 
plasmid and 0.1 μg pf pRL-null vector for 24 hours at 37ºC.  The transfected cells were 
then treated with the vehicle as the control, 100 μM capsaicin, 25 μM DIM individually 
or combination for 24 hours. The cells were harvested in 1x luciferase lysis buffer, and 
luciferase activity was measured. Values are means ± SD, n = 3. Means without a 































Chapter 4. Discussion and Conclusions 
4.1 Discussion 
Cancer remains a major health concern worldwide and current treatment options often 
have debilitating side effects in addition to being expensive and invasive. Therefore there 
is a growing interest in the prevention of cancer by plant-derived, natural compounds due 
to their ability to prevent or halt the initiation and progression of cancer. Many individual 
plant-derived compounds have demonstrated significant effectiveness with minimized 
toxicity in many different types of cancer [6]. It is not just researchers that are interested 
in identifying active compounds in fruits, vegetables and spices to prevent chronic 
disease, but consumers as well. Sales of dietary supplements in the United States totaled 
an estimated $30 billion in 2011[129].  While there is great interest in preventing cancer 
and other chronic diseases through a healthier diet and supplements, more research is still 
needed regarding the efficacy of supplement use across the population.  Decades of 
research on individual phytonutrient and vitamin supplements have resulted in mixed 
outcomes and more questions than answers [4, 5, 96].   
A promising area of research is the identification of novel combinations of phytonutrients 
that have the ability to target multiple pathways involved in the hallmarks of cancer while 
limiting toxic side effects to healthy tissues. With this study, I have analyzed the anti-
cancer properties of the combination of two phytochemicals and compared it with higher 
concentrations of the individual compounds. The interesting finding is that the 
combination of these two compounds exerted significant and sometimes greater anti-
cancer activities than the individual compounds at higher concentrations.  It is significant 
that combination treatment exerted synergistic upregulation of tumor suppressor genes, 
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suppressed oncogenes, inhibited cell proliferation and initiated apoptosis. The hallmarks 
of cancer offer targets of cancer therapy to prevent the initiation or halt the progression of 
cancer given that the dysregulation of multiple pathways involved in the cell cycle and 
apoptotic program is critical for cancer development and progression.  
Both p53 and NF-κB pathways play crucial roles in human cancer; roles that are still 
being investigated due to their complexity [80, 130]. These two pathways have been the 
focus of much research due to the hope that they will offer further insight on the specific 
mechanisms of cancer progression and reveal potential therapeutic targets. The ability of 
the combination of capsaicin and DIM to increase the transcriptional activity of both p53 
and NF-κB is noteworthy. Together these two transcriptional factors regulate hundreds of 
genes that play integral roles in all the hallmarks of cancer and represent promising 
targets for cancer chemoprevention.  
Many of the target genes for p53 are critical to the establishment of the early and late 
stages of cancer, particularly genes involved in apoptosis and cell cycle. Cell cycle 
progression is regulated by coordinated activation of cyclin-dependent kinase 
(cdk)/cyclin complexes. Cyclins bind and activate specific cdk4/6, in association with 
cyclin D1, and cdk2 to phosphorylate proteins of the retinoblastoma tumor suppressor 
(Rb) family. Phosphorylation of Rb determines whether a cell will enter S phase. CDK 
inhibitors, such as p21 and p27, negatively regulate cell cycle progression by inhibiting 
the activity of the cyclin D1/cdk4/6 complexes, thereby decreasing the level of hyper-
phosphorylated Rb [131].  In our study, treatment of capsaicin and DIM induced CDK 
inhibitors (p21 and p27) and proapoptotic proteins (Bak and Fas L) via p53 dependent 
mechanisms (Figure 3.5). 
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Here, we propose two mechanisms by which combination of capsaicin and DIM increase 
apoptosis and changes expression of cell growth and apoptosis-related genes. Firstly, we 
observed that the compounds increased p53 nuclear accumulation (Figure 3.3A) and 
transcriptional activity (Figure 3.3B). p53 accumulation in the nucleus seems to be 
associated with its protein stability. Ser15 phosphorylation of p53 suppresses 
ubiquitination of p53 [132] and subsequent 26S proteasome-mediated degradation by 
reducing the interaction of p53 with E3 ligase, MDM2 and eventually promotes the 
accumulation and transactivation [133]. Most studies support that p53 degradation occurs 
exclusively on cytoplasmic proteasome with focusing on nuclear export of p53 via the 
CRM-1 pathway. However, proteasomes are abundant in both cytosol and nucleus and 
many studies support proteosomal degradation of transcription factors in the nucleus. In 
addition, inhibition of proteasomal degradation using MG-132 leads to localization of 
p65 and p53 in nucleolus (fibrillar centers) compartments [134]. 
Secondly, in the present study, we observed that combination of capsaicin and DIM 
synergistically increased transcriptional activity of NF-κB. The transcription factor NF-
κB is newly recognized as a key mediator of the cellular stress response upon anticancer 
therapy, and the activation of NF-κB can lead to a pro-death response. It is believed that 
increased NF-κB mediates apoptosis induced by anti-cancer agents [135-138]. Thus, 
further study is required to investigate how compounds activate transcriptional activity of 
NF-kB.  
Although the main control of NF-κB activation is cytoplasmic IκB, recently many studies 
propose additional mechanisms that are required to activate or prevent activity of NF-κB 
protein. In fact, NF-κB recruitment is dynamically regulated by multiple signaling inputs 
42 
 
and NF-κB depends entirely on cooperative interactions with partner transcription factors 
for recruitment to some genes. NF-κB also can be regulated in the nucleus by complex 
mechanisms that are still obscure. They include post-translational modification and 
nuclear distribution of p65 which could determine cell fate, pro-apoptotic or anti-
apoptotic, and influence its transcriptional activity. For example, an increased 
accumulation of p65 in nucleoplasm results in apoptosis whereas accumulation of p65 in 
nucleolus is a mechanism of apoptosis activation in response to apoptotic stimuli [139].  
Another interesting point is that p53 and NF-κB have shown an ability to interact with 
each other and coordinate induction of apoptosis. For example, many proapoptotic 
stimuli such as DNA-damaging agents lead to transcriptional co-activation of p53 and 
NF-κB. Ryan et al. suggested that p53 directly activates transcriptional activity of NF-κB 
which is required for p53-induced apoptosis [127]. Other studies demonstrate that p53-
dependent NF-κB activation could contribute to the apoptotic response [128], and the loss 
of p53 could abrogate NF-κB-mediated apoptotic response [140]. p65 has been reported 
to promote apoptosis by actively repressing transcription of antiapoptotic genes through 
association of p65 with histone deacetylase-containing complexes acting as corepressor 
[141]. Overall, even though we did not study direct interaction between p53 and NF-κB, 
it is possible that both NF-kB and p53 may be essential for apoptosis induced by 
combination treatment. Fas ligand (FasL) is believed to be common target for p53 and 
NF-κB and induction of FasL is required for p53- and NF-κB-dependent apoptosis [142-




Although we claim that p53 mediates capsaicin and DIM’s effect, we do not exclude the 
possibility that this combo suppressed cell proliferation and induces apoptosis through 
p53-independent mechanism because some cell lines such as SW480 and Caco-2 are p53 
mutant.  
TRAF2 and TRAF3 are adapter proteins and signal transducers that regulates NF-κB and 
play a role in apoptosis. TRAF3 recruits TRAF2, which forms a heterodimeric complex 
with TRAF1 which then recruits the inhibitor-of-apoptosis proteins (IAPs) and other 
apoptotic suppressors for the inhibition of caspase activation [122]. Therefore, TRAF2 
and TRAF3 are seen as mediating the anti-apoptotic signals from the TNF receptors [145, 
146]. While we did not test to see the effects of the downstream regulation on IAPs as a 
result of treatment, it is noteworthy that two known inhibitors of apoptosis were 
downregulated as a result of combination treatment.   
Another interesting target of apoptosis is NAG-1. NSAID-activated gene-1 (NAG-1) is a 
novel member of the transforming growth factor-beta (TGF-) superfamily and show 
pro-apoptotic and anti-tumorigenic
 
gene in human cancer models including colon, breast, 
and prostate [147]. Transgenic mice overexpressing NAG-1 are resistant to 
azoxymethane (AOM)-induced aberrant crypt foci (ACF), and NAG-1-Tg-Min mice 
showed less tumor load in the small intestine compared with littermate Min control mice 
[148]. NAG-1 expression is induced not only by NSAIDs, but also by several anti-
tumorigenic compounds. Our group already reported that both capsaicin and DIM 
increase expression of NAG-1 [62, 123]. In this study, these compounds synergistically 
increased expression of this tumor suppressor genes and NAG-1 expression is also 
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mediated by status of p53 [149, 150]. These results indicate that NAG-1 acts as a 
molecular target for these two dietary compounds.  
A strength of this study is the number of different cancer lines studied to analyze the 
effects of the phytochemicals. Each cancer cell line has a unique genetic background and 
therefore it is substantial that the compounds exerted significant anti-cancer effects in 
multiple cell lines. 
A limitation of this study is that it is an in vitro design. Therefore, one must use caution 
in extrapolating the data to make application and recommendations in humans. Caution is 
always required because it is not known whether exactly the same signaling mechanisms 
would be operational in vivo and there is a possibility of differences in the therapeutic 
doses in vivo as compared to the concentrations and conditions in vitro. However, studies 
in cell cultures can provide valuable insights into the detailed cellular mechanisms that 
would otherwise be difficult if not impossible to observe in human subjects however, 
more studies are needed, particularly in humans, regarding how combinations of 
phytonutrients such as capsaicin and DIM could help prevent or suppress the initiation 
and progression of cancer.  
4.2 Conclusion 
In conclusion, I believe this study can be used to further confirm the findings of other 
researchers that the combination of multiple phytochemicals can be used to exert greater 
chemopreventative effects rather than a single compound. This is in support of the 
recommendations set by top nutrition authorities to eat at least 5 servings a day of a 
variety of fruits and vegetables.  
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The further study of novel combinations of phytochemicals that have chemopreventive or 
therapeutic activities holds a lot of promise. However, which foods and/or components to 
combine for maximum cancer prevention remain to be determined. Identifying the many 
active components in foods and their mechanisms of action towards cancer prevention is 
still needed. This is very complicated because the effects of dietary components can be 
cell and dose dependent in addition each one can possess multiple mechanisms of action.  
In time, with increased knowledge regarding novel combinations and improved research 
technologies we may be able to identify foods to eat to help prevent specific cancers and 
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